CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
REVENUES:
Grant income	$ 3,671	$ 4,502	$ 3,297
Royalties from product sales and license fees	544	719	398
Subscription and advertisement	972	1,357	1,173
Sale of research products and services	736	458	376
Total revenues	5,923	7,036	5,244
Cost of sales	(358)	(1,107)	(837)
Gross profit	5,565	5,929	4,407
OPERATING EXPENSES:
Research and development	(36,106)	(42,604)	(37,533)
General and administrative	(28,426)	(29,134)	(17,556)
Total operating expenses	(64,532)	(71,738)	(55,089)
Loss from operations	(58,967)	(65,809)	(50,682)
OTHER INCOME/(EXPENSES):
Interest expense, net	(747)	(340)	(89)
BioTime's share of losses and impairment in equity method investment in Ascendance	(4,671)	(35)	0
Gain on deconsolidation of Asterias (Note 3)	49,048	0	0
Gain on equity method investment in Asterias at fair value (Note 4)	34,361	0	0
Gain on investment	0	3,694	0
Other income/(expense), net	(403)	(160)	(384)
Total other income/(expense), net	77,588	3,159	(473)
INCOME (LOSS) BEFORE INCOME TAX BENEFIT	18,621	(62,650)	(51,155)
Deferred income tax benefit	0	4,516	7,376
NET INCOME (LOSS)	18,621	(58,134)	(43,779)
Net loss attributable to noncontrolling interest	14,951	11,143	7,367
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC.	33,572	(46,991)	(36,412)
Preferred stock dividend	0	(415)	(87)
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ 33,572	$ (47,406)	$ (36,499)
NET INCOME (LOSS) PER COMMON SHARE:
BASIC (in dollars per share)	$ 0.35	$ (0.59)	$ (0.55)
DILUTED (in dollars per share)	$ 0.34	$ (0.59)	$ (0.55)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC (in shares)	97,316	79,711	66,467
DILUTED (in shares)	99,553	79,711	66,467